Risk for Conversion of MS Varies With Different Therapies

Share this content:
Risk for Conversion of MS Varies With Different Therapies
Risk for Conversion of MS Varies With Different Therapies

WEDNESDAY, Jan. 16, 2019 (HealthDay News) -- For relapsing-remitting multiple sclerosis (MS), the risk for conversion to secondary progressive MS is lower with initial treatment with fingolimod, alemtuzumab, or natalizumab versus glatiramer acetate or interferon beta, according to a study published online in the Jan. 15 issue of the Journal of the American Medical Association.

J. William L. Brown, M.B.B.S., from the University of Cambridge in the United Kingdom, and colleagues conducted a cohort study with prospective data from 68 neurology centers in 21 countries. They included 1,555 patients with relapsing-remitting MS commencing disease-modifying treatments or clinical monitoring between 1998 and 2012 with a minimum of four years of follow-up.

The researchers found that the risk for conversion to secondary progressive MS was lower for patients initially treated with glatiramer acetate or interferon beta compared with matched untreated patients (hazard ratio, 0.71) and for fingolimod-, natalizumab-, and alemtuzumab-treated patients (hazard ratios, 0.37, 0.61, and 0.52, respectively). Compared with initial treatment with glatiramer acetate or interferon beta, the risk for conversion was lower with fingolimod, alemtuzumab, or natalizumab (hazard ratio, 0.66). When glatiramer acetate or interferon beta was started within five years of disease onset versus later, the probability of conversion was lower (hazard ratio, 0.77).

"These findings, considered along with the risks associated with these therapies, may help inform decisions regarding disease-modifying treatment selection for patients with relapsing-remitting MS," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Operative Treatment Seems Most Effective for Adult Lumbar Scoliosis

Operative Treatment Seems Most Effective for Adult Lumbar ...

Nonoperative tx advised if patient satisfied with spine-related health; surgery may improve outcomes

Intervention Can Reduce Orders for Inpatient Urine Cultures

Intervention Can Reduce Orders for Inpatient Urine Cultures

Intervention includes notifications to providers, changes to order sets, new urine culture reflex tests

Odds of Receiving Tx for CAD Up With Medicare Advantage

Odds of Receiving Tx for CAD Up With ...

However, no significant difference seen in intermediate outcomes for those enrolled in MA, FFS Medicare

is free, fast, and customized just for you!




Already a member?

Sign In Now »